Sichuan Kelun-Biotech Raises $250 Million Through Oversubscribed Share Placement to Boost R&D and Expand Product Pipeline
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced a successful placement of 5,918,000 H shares, raising approximately US$250 million. The shares were issued at HK$331.8 each and represented about 2.54% of the company's expanded share capital. The offering attracted strong interest from investors, being multiple times oversubscribed, with participation from global long-only funds, sovereign wealth funds, and healthcare specialist funds. This placement, the largest in the Hong Kong biopharma sector over the past year, will support the company's pipeline strategy and accelerate global clinical development, aiming to deliver innovative cancer treatments. The funds will be used for research and development, clinical trials, and enhancing internal and external technological capabilities.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN04042) on June 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.